CD19 and acute lymphoblastic leukemia: Consistent with the results of our model, in primary patient data, there are no differences in CD19 or CD22 gene or protein expression between patients with IKZF1 deletions and those with other B-ALL subtypes (Supplementary Fig. 8E, F).